Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's only balloon-expandable, single-piece transcatheter aortic valve. The study aims to assess the safety and feasibility of DurAVR™ THV in treating 15 patients suffering from symptomatic, severe native aortic stenosis, and is critical to obtaining US Food and Drug Administration clearance.
Anteris talks market superiority of its biomimetic TAVR valve
